[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571518":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":90,"collaborators":93,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":28,"studyType":114,"phases":115,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":37,"whyStopped":28,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Clenbuterol Cohort 1","EXPERIMENTAL","20 mcg taken orally twice daily",[13],"Drug: Clenbuterol",{"label":15,"type":10,"description":16,"interventionNames":17},"Clenbuterol Cohort 2","40 mcg taken orally twice daily",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Clenbuterol Cohort 3","60 mcg taken orally twice daily",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Clenbuterol","Beta-Agonist",[9,15,19],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Rebecca Clay","CONTACT","9139459936","rclay@kumc.edu",[36,56,73],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Kansas City","Kansas","66160","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-94.62746,39.11417,{"lat":47,"lon":46},[50,53],{"name":51,"role":32,"phone":52,"phoneExt":28,"email":34},"Rebecca Clay, BS","913-945-9936",{"name":54,"role":55,"phone":28,"phoneExt":28,"email":28},"Jeffrey Statland","PRINCIPAL_INVESTIGATOR",{"facility":57,"status":37,"city":58,"state":59,"zip":60,"country":41,"countryCode":42,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"University of Rochester Medical Center","Rochester","New York","14642",{"type":44,"coordinates":62},[63,64],-77.61556,43.15478,{"lat":64,"lon":63},[67,71],{"name":68,"role":32,"phone":69,"phoneExt":28,"email":70},"Leann Lewis, MSGC","585-275-7680","Leann_Lewis@URMC.Rochester.edu",{"name":72,"role":55,"phone":28,"phoneExt":28,"email":28},"Brianna Brun",{"facility":74,"status":37,"city":75,"state":76,"zip":77,"country":41,"countryCode":42,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"University of Washington","Seattle","Washington","98104",{"type":44,"coordinates":79},[80,81],-122.33207,47.60621,{"lat":81,"lon":80},[84,88],{"name":85,"role":32,"phone":86,"phoneExt":28,"email":87},"Lilly Young","206-616-5957","eyoung8@uw.edu",{"name":89,"role":32,"phone":28,"phoneExt":28,"email":28},"Leo Wang",{"type":91,"investigatorFullName":54,"investigatorTitle":92,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Professor of Neurology",[94,95,98],{"name":74,"class":6},{"name":96,"class":97},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",{"name":99,"class":6},"University of Rochester","100571518","phase-1-clenbuterol-to-target-dux4-in-fshd-100571518",false,"NCT06721299","Clenbuterol to Target DUX4 in FSHD","Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol","Target FSHD","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation\n* between 18 and 75 years of age\n* with a clinical severity score between 0 and 10\n* Able to walk 30ft without support of another person\n* Showing anti-gravity strength on at least one of the tibialis anterior muscles or having an MRI eligible muscle in the leg for needle biopsy\n* willing and able to provide informed consent\n* agree to follow the contraceptive requirement for duration of the study\n\nExclusion Criteria:\n\n* Pregnant or planning to become pregnant during the conduct of the study\n* have a poorly controlled medical condition\n* Were involved in a study of an experimental agent within 3 months of enrollment\n* Are taking beta-blockers or anabolic agent or potassium wasting diuretics\n* Are taking or are planning to take a GLP-1 Agonist during trial\n* have any condition or contraindication which would interfere with testing or preclude use of beta-agonist\n* Are taking blood thinners or medications which make a needle muscle biopsy contra-indicated\n* Has contraindication to lactose such as galactosmia, lactase deficiency and glucose-galactose malabsorption. For those who are lactose intolerant, the PI will determine acceptability based on tolerance reaction to lactose\n* Are taking any medications or therapies with a contraindication to Clenbuterol","ALL","18 Years","75 Years",{"count":112,"type":113},30,"ESTIMATED","INTERVENTIONAL",[116],"PHASE1","The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.",[119],"Muscular Dystrophy, Facioscapulohumeral",[121],"FSHD","2026-02-24",{"date":124,"type":125},"2026-02-25","ACTUAL",{"date":127,"type":125},"2025-06-25",{"date":129,"type":113},"2028-07",{"name":54,"class":6},3]